cardiovascular prevention | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| T1 vs T0 | | | |
Trial | Treatments | Patients | Method |
---|
WARIS, 1990 | warfarin (n=607) vs. placebo (n=607) | patients who had recovered from acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days) | double-blind Sample size: 607/607 Primary endpoint: FU duration: 37 months |
|
coronary artery disease | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| T1 vs T0 | | | |
Trial | Treatments | Patients | Method |
---|
WARIS, 1990 | warfarin (n=607) vs. placebo (n=607) | patients who had recovered from acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days) | double-blind Sample size: 607/607 Primary endpoint: FU duration: 37 months |
|